<DOC>
	<DOCNO>NCT00009191</DOCNO>
	<brief_summary>Major depression afflict approximately 25 percent patient AD . Depression AD patient lead mental suffering , behavioral disturbance ( aggression ) , poor cognition , poor self-care , caregiver depression , caregiver burden , early entry nursing home . Since major depression treatable , additional disability may avoidable . The use antidepressants treat major depression AD support two study , although third show benefit antidepressant placebo . Also , safety antidepressant treatment depress AD patient poorly study . A conclusive study show depression reduction AD accomplish safely antidepressant medication , depression reduction associate improvement activity daily live , non-mood behavioral disturbance , caregiver burden , caregiver depression would major clinical cost implication care AD patient . This study 13-week , double blind , flexible dose , placebo control trial sertraline treatment outpatient AD co-morbid major depression . The hypothesis antidepressant treatment superior placebo improve mood , improve cognition , reduce physical dependency , reduce caregiver depression , reduce caregiver burden . It also hypothesize degree depression reduction correlate improvement . It hypothesize safety profile sertraline compare placebo acceptable , especially regard risk fall , sleep disturbance , delirium . One hundred community reside outpatient probable AD also meet DSM-IV criterion major depressive episode recruit study . They randomize sertraline placebo follow weekly telephone contact experience clinical trial team . Outcomes assess every 3 week , total four followup data point . Scales assess follow domain use : depression , cognition , behavioral disturbance , physical dependency , delirium , fall , sleep , side effect , caregiver depression , caregiver burden , caregiver functioning , caregiver health .</brief_summary>
	<brief_title>The Depression Alzheimer 's Disease Study ( DIADS )</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Sertraline</mesh_term>
	<criteria>Inclusion : Diagnosis Probable Alzheimer 's disease ( AD ) NINCDS/ADRDA criterion ( McKann et al. , 1984 ) , MMSE score great 10 Diagnosis current major depressive episode ( MD ) , DSMIV , base SCIDIV examination Patients include even preAD history unipolar depression Patients currently treat antidepressant continue meet criterion MD ( i.e. , respond medication ) willing discontinue medication enter study also include Currently reside community ( home , family member 's home , small group home ) agree 13 week followup study Stable medical history general health , opinion study psychiatrist A caregiver know patient well ( spends least 10 hour per week ) , reasonably good health , agree participate well Participant his/her legal representative provide inform consent Exclusion : Use sertraline contraindicate , base Food Drug Administration package insert sertraline Patient lifetime diagnosis schizophrenia , bipolar disorder , preAD anxiety disorder , determine SCID Patient current substance use disorder , determine SCID Patient acutely suicidal require inpatient psychiatric hospitalization , determine study psychiatrist No psychotropic medicine dose change , include cholinesterase inhibitor , study entry May enter drug except another antidepressant .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>